Ask a committee of 16 academics, 3 bureaucrats, 2 Fortune 500 executives and 1 Venture Capitalist to provide the President of the United States with a report on improving drug development in the US and they call in a panel of experts consisting of 14 academics, 9 bureaucrats, 12 Fortune 500 execs, 2 venture capitalists and 2 lawyers resulting in: "Report to the President on Propelling Innovation in Drug Discovery , Development and Evaluation".
The recently released report is devoid of any whisper of the existence of entrepreneurs and start-ups. It suggests that more basic research funding, a more efficient drug approval process and longer terms of patent coverage will mysteriously result in more and better therapeutics reaching market.